Briefly, at an in vivo level, they found that small interfering RNA (siRNA)-loaded nanoplexes-based silencing of Satb1, specifically in tumour-associated dendritic cells of mice bearing ID8-Defb29/Vegf-a tumours, significantly enhanced anti-tumour immunity (assessed by the level of infiltration and accumulation of Granzyme B and IFN-γ-secreting antigen-experienced CD44+ cytotoxic T cells) as compared with non-targeting nanoplexes control. The gene discussed is SATB1; the disease is neoplasm.